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Routine Intraoperative Completion
Angiography After Coronary Artery Bypass
Grafting and 1-Stop Hybrid Revascularization
Results From a Fully Integrated Hybrid
Catheterization Laboratory/Operating Room
David X. Zhao, MD, FACC, Marzia Leacche, MD, Jorge M. Balaguer, MD,
Konstantinos D. Boudoulas, MD, Julie A. Damp, MD, James P. Greelish, MD,
John G. Byrne, MD, FACC, the Writing Group on behalf of the Cardiac Surgery, Cardiac
Anesthesiology, and Interventional Cardiology Groups at the Vanderbilt Heart and Vascular Institute
Nashville, Tennessee
Objectives This study sought to report our experience with a routine completion angiogram after coronary artery bypass
surgery (CABG) and simultaneous (1-stop) percutaneous coronary intervention (PCI) at the time of CABG per-
formed in the hybrid catheterization laboratory/operating room.
Background The value of a routine completion angiogram after CABG and 1-stop hybrid CABG/PCI remains unresolved.
Methods Between April 2005 and July 2007, 366 consecutive patients underwent CABG surgery, with (n  112) or with-
out (n  254) concomitant 1-stop PCI (hybrid), all with completion angiography before chest closure. Among the
112 1-stop hybrid CABG/PCI patients, 67 (60%) underwent a planned hybrid procedure based on pre-operative
assessment, whereas 45 (40%) underwent open-chest PCI (unplanned hybrid) based on intraoperative findings.
Results Among the 796 CABG grafts (345 left internal mammary artery, 12 right internal mammary artery/radial, and 439
veins), 97 (12%) angiographic defects were identified. Defects were repaired with either a minor adjustment of the
graft (n  22, 2.8%), with intraoperative open-chest PCI (unplanned hybrid, n  48, 6%) or with traditional surgical
revision (n  27, 3.4%). Hybrid patients had clinical outcomes similar to standard CABG patients.
Conclusions Routine completion angiography detected 12% of grafts with important angiographic defects. One-stop hybrid
coronary revascularization is reasonable, safe, and feasible. Combining the tools of the catheterization labora-
tory and operating room greatly enhances the options available to the surgeon and cardiologist for patients with
complex coronary artery disease. (J Am Coll Cardiol 2009;53:232–41) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.011p
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bith the exception of coronary artery bypass grafting
CABG) surgery, every major cardiovascular intervention—
ncluding percutaneous coronary intervention (PCI),
eart valve surgery, and endovascular and traditional
pen vascular surgery—is accompanied by completion im-
ging to ensure procedural results. However, it has not been
he standard of care to perform completion diagnostic
maging after CABG surgery, primarily because it has been
rom the Vanderbilt Heart and Vascular Institute, Nashville, Tennessee. Funding
nd technical support for this project were provided by the Vanderbilt Heart and
ascular Institute and the Cardiac Surgery Research Fund of Vanderbilt University
edical Center, Nashville, Tennessee.o
Manuscript received June 16, 2008; revised manuscript received October 9, 2008,
ccepted October 14, 2008.reviously either too cumbersome or too logistically difficult.
ecause modern CABG studies report early (12-month)
raft failure rates ranging from 7.6% to 30% (1–3), and
ecause technical errors are thought to be largely responsi-
le, we now routinely perform open-chest completion cor-
nary graft angiography in the hybrid suite with the goal of
nsuring immediate graft quality control. We believe this
ay result in improved short-term and long-term graft
atency.
See page 242
In addition to routine completion angiography, the hy-
rid suite also allows the surgeon and interventional cardi-
logist, in a collaborative environment, to offer patients
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ession. Whereas in diabetic patients, CABG with the left
nternal mammary artery (LIMA) to the left anterior
escending artery (LAD) provides outstanding long-term
esults and survival benefit over PCI or medical manage-
ent (4–8), direct comparison of saphenous vein grafts
SVGs) with PCI has not been documented. Because recent
tudies report close to a 30% SVG occlusion rate within 12
o 18 months (1), and because the 12- to 18-month
estenosis rate with drug-eluting stents (DES) seems supe-
ior to SVG (9–13), we hypothesized that a hybrid surgical
pproach with a LIMA graft to the LAD and PCI approach
ith DES to the right and/or the left circumflex coronary
rteries is a valid alternative to standard CABG in selected
atients.
Conventional bypass surgery is performed in an operating
oom (OR), whereas PCI is performed in a cardiac cathe-
erization laboratory; the physical separation of these 2
rocedural suites poses logistical limitations and potential
isk for 2-staged hybrid revascularization. At Vanderbilt, we
ave constructed a hybrid operating room that combines the
ools of a cardiac catheterization laboratory and an operating
oom into 1 procedural suite.
ethods
he hybrid procedural suite. In 2005, the hybrid room
as constructed in the cardiac catheterization laboratory
uites; the hybrid catheterization laboratory/OR is a fully
unctional catheterization laboratory as well as a fully
unctional OR (Fig. 1). In this 1 procedural suite, every
Figure 1 A Hybrid Operating Room
The Vanderbilt hybrid catheterization laboratory/operating room.ardiovascular procedure can be
erformed, from aortic arch re-
onstruction to routine catheter-
ased intervention.
atients. After obtaining insti-
utional review board approval,
e retrospectively collected data
n 366 consecutive patients who
nderwent CABG surgery with
n  112) or without (n  254)
oncomitant 1-stop PCI from
pril 2005 to June 2007. All
atients enrolled in the study
ere referred for CABG surgery
ased on clinical indications.
onsent was obtained before the
rocedure for intraoperative com-
letion angiography. Before chest closure, an interventional
ardiologist, or a surgeon under the supervision of a cardi-
logist, performed coronary graft angiography. If angio-
raphic defects were identified, revision was carried out
urgically or percutaneously based on the angiographic
ndings. Repeat angiography was then performed to ensure
orrection of these defects before chest closure. For analysis,
independent cardiologists who were not involved in the
are of the patient reviewed each coronary angiogram.
ngiographic defects were divided into 3 categories based
n the location within the graft or target vessel: 1) conduit
efects; 2) anastomotic defects; and 3) target vessel errors.
efect repair methods were subdivided into 3 categories
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
DES  drug-eluting stent(s)
LAD  left anterior
descending artery
LIMA  left internal
mammary artery
OR  operating room
PCI  percutaneous
coronary intervention
SVG  saphenous vein
graft
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djustment of the graft without additional cardiopulmonary
ypass or aortic cross-clamping; 2) intraoperative open-
hest PCI; or 3) traditional surgical revision requiring
dditional cardiopulmonary bypass or aortic cross-clamping
r off-pump revision of surgical anastomosis. Sixty-seven
atients (18%) underwent planned hybrid revascularization.
or these patients, both the cardiac surgeon and the
nterventional cardiologist reviewed the coronary angiogram
n advance. If technically feasible for both surgical and
ercutaneous approaches, the hybrid approach was pre-
ented to the patient and a separate consent was obtained.
atients who underwent planned a hybrid procedure re-
eived 300 mg of clopidogrel orally immediately before
ntering the OR. Unplanned hybrid procedure patients,
hose in whom the decision to perform PCI was based on
ntraoperative findings, received 300 mg of clopidogrel via
asogastric tube at the time the decision for open-chest PCI
as made. All hybrid procedure patients received clopi-
ogrel 75 mg/day for6 months. All patients received daily
25-mg aspirin after the surgery. Before heparinization, a
emoral sheath, for a later catheter-based procedure, was
laced in the left or right femoral artery using the Seldinger
echnique. For on-pump CABG surgery, 300-U/kg heparin
as given to obtain an activated clotting time 400 s. For
re-Operative Characteristics
Table 1 Pre-Operative Characteristics
Variables Entire Group (n  366)
Median age (yrs) 63 (32–89)
Female 95 (26%)
Median body mass index (kg/m2) 29 (15–48)
Hypertension 303 (83%)
Diabetes 143 (39%)
History of smoking 236 (64%)
Dyslipidemia 277 (75%)
Chronic obstructive pulmonary disease 83 (23%)
Median Canadian Cardiovascular Class 2 (1–4)
Unstable angina 202 (56%)
Left main coronary artery stenosis 87 (24%)
Three-vessel disease 245 (67%)
Left ventricular ejection fraction (%) 50 (10–72)
Acute myocardial infarction 49 (13%)
Nonelective surgery 224 (61%)
Prior stroke 30 (8%)
Pre-operative intra-aortic balloon pump 11 (3%)
Low cardiac output syndrome 7 (2%)
Renal failure on hemodialysis 7 (2%)
Prior percutaneous coronary intervention 106 (29%)
Previous cardiac operation 12 (3%)
Median baseline creatinine (mg/dl) 0.9 (0.2–12)
Median baseline platelets (K/l) 220 (60–626)
Median baseline hematocrit (%) 40 (29–55)
Median baseline CPK (U/l) 103 (12–1,787)
Median baseline CK-MB (ng/ml) 4 (0.6–148)
Median baseline troponin I (ng/ml) 0.09 (0.01–4.6)The p value refers to comparison between standard and hybrid groups.
CK-MB  creatine kinase-MB; CPK  creatine phosphokinase.ff-pump CABG, the dose of heparin was 125 U/kg. At the
nd of the surgery, the sheath was typically removed after
he heparin was reversed with protamine, and a Syvek patch
Marine Polymer Technologies, Danvers, Massachusetts)
as applied with 12 min of manual compression of the
roin.
tatistics. Data are expressed as mean and standard devi-
tion or percentage. For continuous variables, a Mann-
hitney U test was used and data were expressed as
edian. The 2-tailed Fisher exact test was used for cate-
orical variables. Data analysis and statistics were performed
ith STATA 9.0 for Windows (Stata Corp., College
tation, Texas).
esults
ompletion angiography after CABG. The entire cohort
f patients underwent completion angiography regardless of
hether or not concomitant PCI (hybrid) was performed.
re-operative characteristics are listed in Table 1, a sum-
ary of grafts performed in Table 2, and operative charac-
eristics in Table 3. There were 97 of 796 (12%) angio-
raphic defects in 89 patients. There were 54 conduit
efects (6.8%), 30 anastomotic defects (3.7%), and 13 target
essel errors (1.6%). A minor adjustment was required in 22
Standard (n  254) Hybrid (n  112) p Value*
63 (32–89) 63 (32–85) 0.29
62 (24%) 33 (29%) 0.18
29 (15–48) 29 (15–48) 0.52
211 (83%) 92 (82%) 0.46
99 (39%) 44 (39%) 0.52
160 (63%) 76 (68%) 0.23
198 (78%) 79 (70%) 0.08
55 (22%) 28 (25%) 0.27
2 (1–4) 2 (1–4) 0.75
140 (55%) 62 (57%) 0.45
67 (27%) 20 (18%) 0.04
160 (63%) 85 (76%) 0.01
54 (10–72) 50 (15–70) 0.26
30 (12%) 19 (17%) 0.11
157 (62%) 67 (60%) 0.42
21 (8%) 9 (8%) 0.56
8 (3%) 3 (3%) 0.57
5 (1.9%) 2 (1.8%) 0.63
5 (1.9%) 2 (1.8%) 0.56
77 (30%) 29 (26%) 0.23
10 (4%) 2 (1.8%) 0.23
0.9 (0.2–12) 0.9 (0.5–5.9) 0.68
220 (98–626) 220 (60–504) 0.66
40 (29–55) 40 (29–50) 0.23
79 (12–1,787) 156 (51–899) 0.04
3 (0.6–148) 6 (0.9–64) 0.03
0.04 (0.01–4.6) 0.2 (0.01–3) 0.40
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nd surgical revision in 27 (3.4%). Twenty-five of 345 (7%)
IMAs had a major defect, of which 10 were located in the
onduit and 15 at the distal anastomosis. Thirty-seven of
45 (8%) SVGs had a major defect, of which 25 were
ocated in the conduit. Angiographic findings versus type of
evision method are summarized in Table 4.
Figures 2 and 3 show examples of defects found on
ompletion angiography: a chest tube obstructing an SVG
efore (Fig. 2A) and after its removal (Fig. 2B); the effect of
n SVG kink of a (reversed) vein valve, before (Fig. 3A) and
fter PCI (Fig. 3B). Intraoperative angiography added an
verage 20  12 min to the surgery and 108  86 ml
ontrast (Visipaque, GE Healthcare, Chalfont St. Giles,
nited Kingdom). Table 5 summarizes post-operative char-
cteristics. In the earlier series of patients (the first 15
onths of the study) the rate of angiographic defects was
5%, whereas in the last 12 months it was 11% (p  0.3).
ybrid CABG/PCI. There were 67 planned and 45 un-
lanned hybrid procedure patients. DES were used in 95 of
12 (84%) and bare-metal stents (BMS) in 9 of 112 (8%). A
ombination of DES and BMS were used in 8 of 112 (7%).
ables 1, 3, and 5 summarize the pre-operative, intraoper-
tive, and post-operative characteristics of hybrid (n  112)
ersus standard CABG (n  254) patients. There was no
ummary of Grafts
Table 2 Summary of Grafts
Graft Type n Total Grafts, % (n  796)
LIMA to LAD 339 41% (93% of all patients)
LIMA to other 6 1%
SVG to LAD 18 3%
SVG to RCA 47 6%
SVG to PDA 84 11%
SVG to OM 180 22%
SVG to ramus 41 5%
SVG to diagonals 69 9%
RIMA/radials 12 2%
AD  left anterior descending artery; LIMA  left internal mammary artery; OM  obtuse
arginal; PDA  posterior descending artery; RCA  right coronary artery; RIMA  right internal
ammary artery; SVG  saphenous vein graft.
Operative Characteristics
Table 3 Operative Characteristics
Variable Entire Group (n  366)
CABG alone 235 (64%)
CABG  PCI 112 (31%)
CABG  other† 19 (5%)
Mean no. of stents N/A
Off pump 39 (11%)
AoX (min) 59 (12–218)
CPB time (min) 87 (27–284)
Contrast (ml) 100 (20–800)
OR time (min) 389 (154–775)
*The p value refers to comparison between standard and hybrid grou
surgery, n  3; CABG  left ventricular aneurysm, n 2.
AoX  aortic cross clamping; AVR  aortic valve replacement; C
MVR/TV  mitral valve replacement/tricuspid valve replacement; N/A  n
intervention.ignificant difference in operative mortality between hybrid
n  3, 2.6%) versus standard CABG (n  4, 1.5%) (p 
.33, 95% confidence interval: 0.060 to 0.019). The
ndications for planned hybrid procedures (n 67) included
n attempt to minimize surgical risk (n 32), poor conduits
n  3), ungraftable vessels (n  29), or stenting of the left
ubclavian artery (n  3) (Table 6). In unplanned hybrid
rocedures (n  45), the decision for open-chest PCI was
ased on intraoperative findings. The indications for un-
lanned PCI were graft defects (n  43) identified by
outine completion angiogram, poor conduits (n  1), or
ngraftable vessels (n  2). One patient underwent both
planned left subclavian stenting and unplanned PCI for
raft defect). These 43 PCI-treated defects are a subset of
he 97 total defects identified by intraoperative angiography.
he remaining 54 defects were treated surgically. The
iming and sequence of the hybrid procedures are summa-
ized in Table 6.
Two patients (0.5%) sustained catheter-related com-
lications: 1 unplanned hybrid procedure patient devel-
ped a small perforation of the posterior descending
rtery, managed percutaneously, and 1 planned hybrid
rocedure patient sustained an injury of the femoral
rtery requiring open surgical repair because of an en-
arging hematoma. One of 112 hybrid procedure patients
1%) sustained acute stent thrombosis and died. Another
atient who underwent balloon angioplasty of a small
osterior descending artery had a reocclusion after the
rocedure and underwent reopening of the vessel with
uccessful stenting.
iscussion
ntraoperative completion angiography. The clinical im-
act of SVG failure was documented in a randomized study
f 3,041 patients, wherein the common end point of death
nd new myocardial infarction was more common if SVG
ailure was present (14% vs. 1%) (1). The impact of SVG
ailure was even more pronounced if the need for revascu-
arization was added to death and new myocardial infarction
ard (n  254) Hybrid (n  112) p Value*
(93%) N/A N/A
N/A 112 N/A
(7%) 0 N/A
N/A 1.8 1.1 N/A
(6.7%) 22 (20%) 0.001
(12–218) 56 (18–205) 0.022
(27–284) 83 (31–278) 0.047
(20–800) 200 (20–550) 0.001
(171–681) 421 (154–775) 0.001
BG  AVR, n  6; CABG  MVR/TV surgery, n  8; CABG  root/arch
coronary artery bypass grafting; CPB  cardiopulmonary bypass;Stand
235
19
17
60
89
80
377
ps. †CA
ABG 
ot applicable; OR  operating room; PCI  percutaneous coronary
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ngiography documented that the SVG graft failure rate
as 30%, whereas the LIMA failure rate was 8% (1).
echnical errors are believed to be responsible for early graft
ailure, which is present in 5% to 20% of patients at
ischarge (14). In the current study, we identified that 12%
f all grafts had some form of angiographic defect, which
ay have otherwise been missed intraoperatively. Comple-
ion angiography changed surgeon behavior in the operating
Figure 2 Completion Angiogram of SVG Before and After Revis
Completion angiography after coronary artery bypass grafting surgery showing a ch
saphenous vein graft (SVG) to the posterior descending artery graft (PDA) (yellow
ocation of Angiographic Graft Finding Versus Type of Graft Interve
Table 4 Location of Angiographic Graft Finding Versus Type of
Type of Graft Intervention
Conduit
(n  54 of 796, 6.8% of All
Traditional open surgical revision, n  27 of 796,
3.4% of all grafts
12 grafts
Clip damaging LIMA (n  3)
Suture damaging LIMA (n  1
Graft kink not correctable with
adjustment (n  6)
SVG valve impeding flow (n 
Open-chest PCI, n  48 of 796, 6% of all grafts
(n  43 unplanned hybrid procedure patients†)
23 grafts:
SVG valve impeding flow
(n  9)
LIMA dissection (n  6)
Graft kink (n  7)
SVG–coronary size mismatch
Minor adjustment of graft not requiring traditional
surgical revision or open-chest PCI, n  22 of
796, 2.8% of all grafts
19 grafts:
Adjustment of conduit lie (n 
Clip removal (n  1)
Stitch removal (n  1)
Chest tube removal (n  2)
Intravenous nitroglycerin for L
spasm (n  4)
Unroofing of fascia on SVG co
that had caused kinking (n
Note: the denominator in the table is 796 (grafts), not 366 (patients). †See Table 5: some patie
Abbreviations as in Table 3.oom by providing immediate feedback on issues that were
ifficult to appreciate with the naked eye. We became more
elective regarding the significance of apparently minor (to
he naked eye) kinks in vein grafts, the effect of (reversed)
ein valves on antegrade flow, and the effect of conduit-
arget mismatch, in which the SVG diameter is significantly
reater than the target vessel. These considerations were
erhaps only minor considerations before our use of routine
ompletion angiography. Although the technique for
be compressing the
before (A) and after (B) repositioning of chest tube.
*
Intervention*
Location of Angiographic Findings in Grafts
)
Distal Anastomosis
(n  30 of 796, 3.7% of All Grafts)
Target Vessel
(n  13 of 796, 1.6% of All Grafts)
r
12 grafts:
LIMA-LAD (n  11)
SVG (n  1)
3 grafts:
Correct vessel, wrong location
(n  1)
Wrong vessel (n  2)
)
15 grafts:
SVG (n  11)
LIMA-LAD (n  4)
10 grafts:
Correct vessel, wrong location
(n  7)
Wrong vessel (n  1)
Poor runoff, diffuse disease (n  1)
Dissection in the native coronary
(n  1)
3 grafts:
Unroofing of fascia over the
anastomosis (n  3)
N/A
1 PCI.ion
est tu
arrow)ntion
Graft
Grafts
)
mino
2)
(n  1
7)
IMA
nduit
 4)
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January 20, 2009:232–41 Angiogram After CABG and Hybrid ProceduresFigure 3 Intraoperative Bypass Graft Angiogram Before and After Revision With Percutaneous Coronary Intervention
Intraoperative angiography showing a vein kink (proximal) and (reversed) vein valve (distal) in the saphenous vein graft to the second obtuse marginal artery (panel A-a)
causing new acute ischemic mitral regurgitation (panel A-b) with reversal of flow in the pulmonary veins (panel A-c); after percutaneous coronary intervention of the kink
and vein valve, the improved runoff in recruited collaterals (panel B-a), with resolution of the mitral regurgitation (panel B-b) and pulmonary vein flow reversal (panel
B-c). Reprinted, with permission, from Greelish JP, Eagle SS, Xhao DX, et al. Management of new-onset mitral regurgitation with intraoperative angiography and intraoper-
ative percutaneous coronary intervention. J Thorac Cardiovasc Surg 2006;131:239–40.
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5 years, the technical difficulties of performing CABG
ave increased over time, because of the presence of more
iffuse coronary artery disease and smaller coronary targets,
specially in diabetic patients, the very population in whom
ABG affords the most benefit.
We also observed a 7% (25 of 345) incidence of LIMA
ngiographic findings, remarkably similar to the findings
n the PREVENT IV (Project of Ex-Vivo Vein Graft
ngineering via Transfection) trial (1), in which 8% of
IMA grafts had a significant defect at 1 year. We
elieve the 8% defect rate in the PREVENT IV trial
ikely represents findings that could have been corrected
t the time of surgery. Our data, together with the
ost-Operative Characteristics
Table 5 Post-Operative Characteristics
Variables Entire Group (n  36
Median chest tube drainage (ml) 1,420 (110–12,700
Reoperation for bleeding 10 (3%)
Median PRBC transfusions (units/patient) at 48 h 1 (0–20)
Median creatinine at 24 h (mg/dl) 0.9 (0.3–12.1)
Median creatinine at 48 h (mg/dl) 1 (0.3–12.3)
Median creatinine at 72 h (mg/dl) 1 (0.3–13.2)
Median CPK at 48 h (U/l) 906 (189–7,788)
Median CK-MB at 48 h (ng/ml) 16 (2–164)
Median CK-MB ratio at 48 h (%) 1.6 (0.5–8.4)
Median troponin I at 48 h (ng/ml) 0.4 (0.01–4.6)
New acute renal failure 13 (4%)
25% increase in creatinine at 72 h 126 (34%)
New stroke 5 (1.4%)
New renal failure requiring hemodialysis 3 (1%)
New atrial fibrillation 83 (23%)
New intra-aortic balloon pump 13 (4%)
Intrastent thrombosis 1 (0.3%)
New low cardiac output syndrome 10 (3%)
Deep sternal wound infection 5 (1%)
Median length of stay (days) 5 (1–97)
Operative mortality 7 (2%)
The p value refers to comparison between the standard and hybrid groups.
CK-MB  creatine kinase-MB; CPK  creatine phosphokinase; PRBC  packed red blood cells.
lanned Versus Unplanned Hybrid Groups
Table 6 Planned Versus Unplanned Hybrid Groups
Planned
(n  67)
Unplanned
(n  45)
Indication for PCI
Attempt to decrease risk 32 0
Poor conduit 3 1
Graft defect 0 43*
Left subclavian stenosis 3* 0
Nongraftable vessel/favorable PCI lesion 29 2
Timing of PCI
Closed-chest PCI before open surgery 41 0
Open-chest PCI after open surgery 26 45
Operative mortality 1 (1.5%) 2 (4.4%)s
1 patient with 2 procedures (stenting of the left subclavian  unplanned PCI).
PCI  percutaneous coronary intervention.REVENT IV data, further support our argument that
ntraoperative imaging should perhaps eventually become
he standard of care for CABG surgery. Our defect rate
ecreased from 15% to 11% during the study period, and
e anticipate that we will continue to improve as we
ontinue to measure our performance. Long-term (12-
onth) graft computed tomography angiographic
ollow-up for these patients is in progress, and we
ypothesize that correction of these defects at the time of
urgery may help reduce the rate of graft failure.
ybrid CABG/PCI. The LIMA-LAD bypass has been
hown to be the most durable and proven treatment to
ignificantly reduce the subsequent risk of death, myocardial
nfarction, recurrent angina, and the need of further revas-
ularization (15,16). However, the benefit of surgical revas-
ularization after LIMA-LAD remains less clear (8). This is
eflected in the lack of survival benefit in reoperative CABG
urgery when the LIMA is already patent (17). Thus, as PCI
ontinues to improve, the future of CABG may possibly be
imited to the LIMA-LAD performed through a small ante-
ior thoracotomy with PCI to non-LAD vessels (18).
Whether non-LAD vessels should be grafted, stented, or
eft alone will need to be determined based on conduit and
arget vessel quality. These considerations suggest that
elected patients might benefit from a combined planned
ybrid approach. In our series this planned hybrid approach
as used in 67 (18%) patients whom the cardiologist and
ardiac surgeon believed would be better served by a
ombined approach rather than by conventional CABG
Standard (n  254) Hybrid (n  112) p Value*
1,382 (170–7,240) 1,550 (110–12,700) 0.18
7 (3%) 3 (3%) 0.63
1 (0–20) 1 (0–10) 0.13
0.9 (0.3–12.1) 0.9 (0.4–5) 0.90
1 (0.4–12.3) 1 (0.3–5.9) 0.78
1 (0.3–13.2) 1 (0.4–4) 0.58
452 (189–7,788) 1,492 (736–6,430) 0.01
10 (2–140) 28 (11–164) 0.01
1.4 (0.5–8.4) 1.9 (0.6–2.7) 0.33
0.3 (0.03–1.8) 1.2 (0.01–4.6) 0.42
10 (3.9%) 3 (2.6%) 0.39
89 (35%) 37 (33%) 0.40
3 (1.1%) 2 (1.7%) 0.48
3 (1%) 0 (0%) 0.33
61 (24%) 22 (19%) 0.21
7 (3%) 6 (5%) 0.17
N/A 1 (1%) N/A
5 (1.9%) 5 (4.5%) 0.15
3 (1%) 2 (1.8%) 0.48
5 (1–33) 6 (1–97) 0.08
4 (1.5%) 3 (2.6%) 0.336)
)urgery.
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January 20, 2009:232–41 Angiogram After CABG and Hybrid ProceduresFor planned hybrid procedure patients, in centers without
hybrid suite, a 2-stage approach, using 2 suites (a tradi-
ional OR and traditional catheterization laboratory), is
ertainly reasonable. In a 2-stage hybrid procedure, either
ABG or PCI is performed first followed days later by the
ther procedure. The CABG first staging is probably
referable because it avoids clopidogrel-related bleeding
omplications during CABG, has the advantage of a pro-
ected environment with a (presumably perfectly patent)
IMA-LAD graft, and the LIMA graft patency can be
erified at the time of PCI (although any defects identified
ays after CABG could likely only be addressed with PCI).
he only disadvantage of the CABG first staging is that, in
he event of PCI complication/failure, a second and much
igher-risk operation would need to be performed.
hether CABG or PCI is performed first, in both scenar-
os, 2 procedures need to be performed with 2 operative
osts and 2 operative teams. A 1-stop procedure, as de-
cribed in the current report, has the advantage of avoiding
he potential problems related to 2 separate procedures and
ands-off, but also any complications can be resolved in 1
etting, and graft patency can be confirmed immediately.
lso, many patients just do not want to undergo 2 procedures.
Forty-five (40%) hybrid procedure patients had an un-
lanned hybrid procedure that was performed based on
ntraoperative findings either because of graft defects, a poor
onduit, or an ungraftable coronary vessel. Had these
perations been performed in a standard operating room,
hese patients may have left the OR with a suboptimal
esult. Once a defect was discovered on completion angio-
ram, the decision for unplanned PCI versus surgical
evision was made by consultation between a cardiac sur-
eon and an interventional cardiologist. PCI was the pre-
erred method for revising angiographic defects when they
ere located in the conduit or target vessel, whereas
raditional surgical revision was more commonly used for
nastomotic revisions. In a traditional setting, without PCI
s an option—provided a defect could be identified—the
nly choice would have been to harvest another conduit
nd/or repeat the anastomosis with the potential for another
onduit of poor quality. Consistent with prior reports, we
sed DES in the revision of an SVG conduit rather than
MS, which results in lower restenosis rates (19).
Our inability to document a lower operative risk in hybrid
ABG/PCI patients, in contrast to our prior study on
ybrid valve/PCI patients in which we showed a reduction
n the observed mortality (20), is probably attributable to the
act that CABG is, in general, a lower-risk endeavor, and
herefore, it is more difficult to prove a benefit.
leeding complications versus stent thrombosis. A ma-
or concern with the hybrid approach is the need for
ntiplatelet agents. In a prior study on hybrid valve/PCI
atients, we documented an increased amount of chest tube
utput, reoperation for bleeding, and transfusions require-
ents (20). In the present series, 19% of the patientsnderwent their procedures while on clopidogrel, and 31% leceived clopidogrel as part of their hybrid procedure. We
ound similar chest tube output drainage, and the rate of
eoperation for bleeding was not different between groups.
Acute stent thrombosis is an important complication and
potential major limitation of the hybrid procedure. In our
eries, 1 of 112 (1%) patients developed acute in-stent
hrombosis and died. This was an elderly man with severe
scending aortic disease in whom a tight left main lesion
as present. We performed LIMA-LAD off-pump fol-
owed by left main PCI. The patient developed acute stent
hrombosis after heparin reversal and died. Although this
ate of stent thrombosis was within the reported rate of
cute stent thrombosis (21), we believe that antiplatelet
trategies need particular attention in hybrid procedure
atients because of the need to reverse heparin with prota-
ine. Because the antiplatelet effect of clopidogrel is both
ime and dose dependent with a maximal inhibition of
latelet aggregation 4 to 24 h after a dose of 300 to 600 mg
22,23), we currently administer the dose of clopidogrel
mmediately before surgery in the holding area for a planned
ybrid procedure or, for an unplanned hybrid procedure,
uring the surgery at the time the decision for PCI is made.
e also use a 300-mg loading dose rather than 600 mg, as
iven for isolated PCI, as a compromise to balance the risk
f significant bleeding against stent thrombosis. The anti-
latelet effects of cardiopulmonary bypass may be protective
gainst the risk of stent thrombosis (24). Thus, antiplatelet
trategies may need to be more intense with off-pump
ybrid CABG/PCI patients. Also, patient response to
lopidogrel may differ and pre-operative platelet studies may
elp to identify patients with potential clopidogrel resis-
ance. An alternative to heparin in selected hybrid procedure
atients is bivalirudin (25). Currently, however, there is no
onsensus on the best monitoring strategy for bivalirudin
nticoagulation on cardiopulmonary bypass.
ardiac catheterization–related complications. We
laced the femoral arterial sheath before heparinization to
void potential access site hematomas, and we report 1
atient (0.5%) with arterial access complication. We also
voided completion angiography in patients with advanced
ascular disease (grade 4 to 5 atheroma in the descending
horacic aorta on transesophageal echocardiogram). Al-
hough we report a 1% incidence of new stroke, it is difficult
o determine whether stroke was catheter or surgery related.
ur data support that angiography should be performed in
he vast majority of patients undergoing CABG in the
ybrid suite. We also acknowledge that there are important
ifferences between diagnostic angiography and completion
ngiography. In the latter, there are fresh proximal and
istal anastomoses and the hemodynamic changes associ-
ted with the post-operative condition. However, with
areful technique, our interventional cardiologists were able
o perform completion angiography with a very low rate of
atheter-related complications.
nfectious complications. We were exceedingly meticu-
ous about sterile technique, and we report a sternal wound
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ith an open chest, and the camera is moved into place over
he open chest, we have adopted the practice of quintuple
raping (3 drapes on the open wound and 2 on the camera).
ecause the hybrid suite contains many more moving parts,
nd more personnel are involved, infection control is exceed-
ngly important. Team discipline, control of traffic, and polic-
ng of behavior are crucial for a successful hybrid program.
enal complications. Contrast nephropathy is another ma-
or concern of intraoperative angiography and a hybrid ap-
roach. We document a low incidence of new renal failure
4%). Our experience was consistent with previous reports that
ngiography after cardiac surgery is safe without increased risk
f contrast nephropathy (26). Moreover, in the hybrid group,
e did not observe an increased rate of acute renal failure or an
ncrease of serum creatinine, despite greater contrast load
ompared with the completion angiography group. We cur-
ently do not perform a routine completion angiogram if the
re-operative creatinine value is 2.0 mg/dl.
dded time and cost. As expected, there was a learning
urve and much of the added time early in the series was
elated to our caution with all of the moving parts, all of the
ifferent personnel involved, as well as our goal of training
urgeons in catheter-based techniques. However, as sur-
eons become more adept at completion angiography, this
dded time will likely be reduced significantly.
Building hybrid suites is certainly more expensive than
uilding either a standard operating room or a standard
atheterization laboratory. However, this all-purpose hybrid
uite can be used for every cardiovascular procedure, includ-
ng traditional cardiac surgery, traditional vascular surgery,
ndovascular aortic procedures, electrophysiology proce-
ures, or interventional coronary procedures. There is also a
nancial benefit of synergy of teams, cross-training person-
el, with overlapping of the OR team with the interven-
ional team.
tudy limitations. This was a retrospective study with
nherent selection bias. The decision to perform the hybrid
rocedure was made by the surgeon and the interventional
ardiologist on an individual and highly selective basis.
mplications and the hybrid paradigm. Our data suggest
hat routine completion graft imaging should eventually
ecome the standard of care in CABG surgery. Further-
ore, with the increased complexity of patients referred for
ardiac surgery, a team approach, combining traditional
ardiac surgical techniques and PCI, may be beneficial,
specially in high-risk populations.
The technology used in a hybrid OR is well estab-
ished, but the ability to combine them into 1 operative
uite can be challenging. This requires a high level of
ollaboration between interventional cardiologists and
ardiac surgeons. The willingness and ability to form this
ollaborative working environment seems to be the great-
st barrier (27).
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